Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CFTX-1554 in Healthy Subjects, With Comparison of Intake of CFTX-1554 as Liquid Formulation and as Capsule, and After a High-fat Breakfast Versus Fasted

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CFTX-1554 in Healthy Subjects, With Comparison of Intake of CFTX-1554 as Liquid Formulation and as Capsule, and After a High-fat Breakfast Versus Fasted

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CFTX-1554 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; First in man
  • Sponsors Confo Therapeutics

Most Recent Events

  • 29 Jul 2024 According to a Confo Therapeutics media release, the comapany announces EUR 60M series B financing to advance pipeline of Novel GPCR-Modulating therapies into clinical development the proceeds will be used to advance two, wholly owned programs through Phase 1.
  • 01 Sep 2023 Status changed from recruiting to completed.
  • 10 Mar 2022 According to a Confo Therapeutics media release, first subjects have been dosed in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top